Dividend Information About Humana: Everything You Need to Know Before Its Ex-Dividend Date of Sep 26, 2025

Humana (HUM) has announced a cash dividend of $0.8850 per share, with the ex-dividend date set for Sep 26, 2025. Investors must own shares before this date to qualify for the dividend, which will be distributed on Oct 31, 2025. The dividend was officially announced on Aug 21, 2025, maintaining the company's consistent cash payout structure. This upcoming dividend is significantly higher than the average of the last 10 dividend payments, which stood at approximately $0.3453 per share. The most recent dividend was paid on Jul 25, 2025, with the same amount of $0.8850 per share, continuing the company’s pattern of regular cash distributions. Investors should note that the ex-dividend date of Sep 26, 2025, is the final opportunity to purchase the stock and receive this dividend, as any transactions after this date will not qualify for the payout.

Recently, several key developments have emerged that could influence Humana’s stock performance and business strategy. Over the past week, analysts have highlighted the company’s strong position in the Medicare Advantage (MA) sector, with improved margin recovery trajectories suggesting a positive outlook for its operational efficiency. Source reported that Humana’s strategic integration of payer and provider models, particularly through its subsidiary CenterWell, is enabling the company to streamline care delivery and reduce hospital readmissions. This approach is especially beneficial for managing complex patient populations, as it aligns incentives across care settings and enhances overall service quality. Since the last update, the firm has also seen increased investor interest, with Diversified Trust Co acquiring a new position in HUM shares during the second quarter, signaling confidence in its long-term growth prospects.

As of late, Evercore ISI Group initiated coverage of Humana with an In-Line rating and a price target of $295, reflecting analysts' view that the company is well-positioned to navigate industry challenges. Source indicated that the firm is cautiously optimistic about the potential for rate adjustments in the MA space, which could support future profitability. Additionally, Humana’s pilot programs and rapid deployment capabilities have been cited as competitive advantages in the evolving healthcare landscape. These initiatives are expected to drive innovation in care delivery models and reinforce the company’s leadership in home-based and integrated care solutions.

Humana remains a key player in the health insurance sector, with over five million Medicare Advantage members and a growing provider network. Its payvider model continues to attract attention for its ability to bridge the gap between payer and provider operations, fostering a more cohesive and patient-centric healthcare system. As industry trends evolve, the company’s ability to adapt and innovate will likely remain a cornerstone of its competitive edge.

Investors should be aware that the ex-dividend date of Sep 26, 2025, is the last day for investors to buy the stock and receive the upcoming $0.8850 per share dividend. Any purchase after this date will not entitle investors to participate in the payout.